223 related articles for article (PubMed ID: 34901581)
21. International Regulatory Collaboration on the Analysis of Nitrosamines in Metformin-Containing Medicines.
Keire DA; Bream R; Wollein U; Schmaler-Ripcke J; Burchardt A; Conti M; Zmysłowski A; Keizers P; Morin J; Poh J; George M; Wierer M
AAPS J; 2022 Apr; 24(3):56. PubMed ID: 35449372
[TBL] [Abstract][Full Text] [Related]
22. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
23. GFP-fused yeast cells as whole-cell biosensors for genotoxicity evaluation of nitrosamines.
He Y; Ding H; Xia X; Qi W; Wang H; Liu W; Zheng F
Appl Microbiol Biotechnol; 2021 Jul; 105(13):5607-5616. PubMed ID: 34228183
[TBL] [Abstract][Full Text] [Related]
24. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
[TBL] [Abstract][Full Text] [Related]
25. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
Charoo NA; Dharani S; Khan MA; Rahman Z
AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
[TBL] [Abstract][Full Text] [Related]
27. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis.
Hecht SS
Proc Soc Exp Biol Med; 1997 Nov; 216(2):181-91. PubMed ID: 9349687
[TBL] [Abstract][Full Text] [Related]
28. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products.
Snodin DJ; Elder DP
Regul Toxicol Pharmacol; 2019 Apr; 103():325-329. PubMed ID: 30629969
[TBL] [Abstract][Full Text] [Related]
29. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
30. What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure-Activity Relationships.
Thomas R; Tennant RE; Oliveira AAF; Ponting DJ
Chem Res Toxicol; 2022 Nov; 35(11):1997-2013. PubMed ID: 36302501
[TBL] [Abstract][Full Text] [Related]
31. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
[TBL] [Abstract][Full Text] [Related]
32. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
33. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
34. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
[TBL] [Abstract][Full Text] [Related]
35. Metabolic fate and carcinogenicity of N-(omega-hydroxyalkyl) N-(4-hydroxybutyl) nitrosamines analogs of N-butyl-N-(4-hydroxy-butyl) nitrosamine, in the rat.
Suzuki E; Takeda Y; Mochizuki M; Hashimoto Y; Okada M
Gan; 1981 Aug; 72(4):539-46. PubMed ID: 7308665
[TBL] [Abstract][Full Text] [Related]
36. Carcinogenicity of N-nitrosamines related to N-butyl-N-(4-hydroxybutyl)nitrosamine and N,N,-dibutylnitrosamine in ACI/N rats.
Okada M; Suzuki E; Hashimoto Y
Gan; 1976 Dec; 67(6):825-34. PubMed ID: 191321
[TBL] [Abstract][Full Text] [Related]
37. [Quantitative structure-activity relationship prediction of carcinogenicity of N-nitroso compounds based on category approach and read-across].
Liang QQ; Zheng WW; He GS; Qu WD
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):621-627. PubMed ID: 28693087
[No Abstract] [Full Text] [Related]
38. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products.
Golob N; Grahek R; Ross M; Roškar R
Int J Pharm; 2022 Apr; 618():121687. PubMed ID: 35314277
[TBL] [Abstract][Full Text] [Related]
39. Quantification of Total N-Nitrosamine Concentrations in Aqueous Samples via UV-Photolysis and Chemiluminescence Detection of Nitric Oxide.
Breider F; von Gunten U
Anal Chem; 2017 Feb; 89(3):1574-1582. PubMed ID: 27989108
[TBL] [Abstract][Full Text] [Related]
40. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
